13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • NABNEC

    Acronym: 

    NABNEC

    ACTRN/NCT /ethics: 

    ACTRN12616000958482; Ethics 163.17

    Scientific title: 

    A randomised phase II study to establish if carboplatin and nab-paclitaxel combination is an effective and tolerable chemotherapy treatment for grade 3 advanced gastrointestinal Neuroendocrine Carcinomas.

    Summary of trial and patient characteristics

    Cancer Type Neuroendocrine
    Trial Type Treatment
    Phase Phase II Tumour Stream Colorectal
    Age Range 18 years and older Cancer Stage Locally Recurrent or Locally Advanced
    Sex Both Anticipated Start Date 2016-08-19
    Molecular Target Anticipated End Date
    Cancer Type Neuroendocrine
    Trial Type Treatment
    Phase Phase II
    Age Range 18 years and older
    Sex Both
    Molecular Target
    Tumour Stream Colorectal
    Cancer Stage Locally Recurrent or Locally Advanced
    Anticipated Start Date 2016-08-19
    Anticipated End Date

    Trial Summary

    The primary purpose of this trial is to evaluate the safety and efficacy of carboplatin plus nab-paclitaxel in comparison with carboplatin plus etoposide chemotherapy for the treatment of gastrointestinal neuroendocrine carcinomas (NECs).

    Lay Summary

    A randomised phase II study to establish if carboplatin and nab-paclitaxel combination is an effective and tolerable chemotherapy treatment for grade 3 advanced gastrointestinal Neuroendocrine Carcinomas.

    Sponsor / Cooperative group

    Australasian Gastro-Intestinal Trials Group (AGITG)

    Participating Hospitals

    Hospital Clinical Trial Coordinator Email Phone Principal Investigator Recruitment Status
    Flinders Medical Centre Alex Scott-Hoy alex.scott-hoy@sa.gov.au 08 8204 4830 Chris Karapetis Recruiting